254 related articles for article (PubMed ID: 30069818)
1. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines.
Yang J; Gong Y; Sontag DP; Corbin I; Minuk GY
Mol Biol Rep; 2018 Oct; 45(5):1023-1036. PubMed ID: 30069818
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats.
Wen X; Reynolds L; Mulik RS; Kim SY; Van Treuren T; Nguyen LH; Zhu H; Corbin IR
Gastroenterology; 2016 Feb; 150(2):488-98. PubMed ID: 26484708
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells.
Reynolds L; Mulik RS; Wen X; Dilip A; Corbin IR
Nanomedicine (Lond); 2014 Jul; 9(14):2123-41. PubMed ID: 24397600
[TBL] [Abstract][Full Text] [Related]
5. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
[TBL] [Abstract][Full Text] [Related]
6. Assessing the safety of transarterial locoregional delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat liver.
Li J; Canseco D; Wang Y; Vale G; Chaudhary J; Anwar A; Baniasadi H; Williams NS; Gopal P; Sutphin PD; McDonald JG; Putnam WC; Corbin IR
Eur J Pharm Biopharm; 2021 Jan; 158():273-283. PubMed ID: 33242579
[TBL] [Abstract][Full Text] [Related]
7. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
[TBL] [Abstract][Full Text] [Related]
8. Investigation into the distinct subcellular effects of docosahexaenoic acid loaded low-density lipoprotein nanoparticles in normal and malignant murine liver cells.
Moss LR; Mulik RS; Van Treuren T; Kim SY; Corbin IR
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2363-2376. PubMed ID: 27418237
[TBL] [Abstract][Full Text] [Related]
9. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
10. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the structural organization of a novel low-density lipoprotein nanoparticle reconstituted with docosahexaenoic acid.
Mulik RS; Zheng H; Pichumani K; Ratnakar J; Jiang QX; Corbin IR
Chem Phys Lipids; 2017 Apr; 204():65-75. PubMed ID: 28342772
[TBL] [Abstract][Full Text] [Related]
12. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Lim K; Han C; Dai Y; Shen M; Wu T
Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
[TBL] [Abstract][Full Text] [Related]
14. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
16. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
17. A novel nitidine chloride nanoparticle overcomes the stemness of CD133
Li D; Zhang Q; Zhou Y; Zhu H; Li T; Du F
BMC Pharmacol Toxicol; 2022 Jul; 23(1):48. PubMed ID: 35820920
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
19. Influence of Docosahexaenoic Acid on Proliferation and Apoptosis in Human HepG2 Cell Line.
Chen YJ; Jiang HT; Wang TF
Ann Clin Lab Sci; 2019 Jan; 49(1):72-78. PubMed ID: 30814080
[TBL] [Abstract][Full Text] [Related]
20. An implanted port-catheter system for repeated hepatic arterial infusion of low-density lipoprotein-docosahexaenoic acid nanoparticles in normal rats: A safety study.
Wang Y; Li J; Subramaniyan I; do Vale GD; Chaudhary J; Anwar A; Wight-Carter M; McDonald JG; Putnam WC; Qin T; Zhang H; Corbin IR
Toxicol Appl Pharmacol; 2020 Aug; 400():115037. PubMed ID: 32417438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
